Discover 1,248 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The city’s leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Filter
2
Filter results
Results: 1,248
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
for
Non-Small Cell Lung Cancer
Location: Nashville TN, Atlanta GA, St Louis MO, Columbus GA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07100080
Phase2, Phase3, Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
for
Breast Neoplasms
Location: Nashville TN, Louisville KY, Germantown TN, O'Fallon IL,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07173751
Phase3, Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Nashville TN, Birmingham AL, St Louis MO, Dayton OH,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06973187
Phase3, Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells
for
Long Term Safety Following GM T Cell Therapy
Location: Nashville TN
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06798298
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
for
Metastatic Castration Sensitive Prostate Cancer (mCSPC),
Location: Nashville TN, Hendersonville TN, Franklin TN, Smyrna TN,
Sponsor: Pfizer
Sex: Male
Age: 18+
Code: NCT07028853
Phase3, Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
for
Breast Neoplasms
Location: Nashville TN, Indianapolis IN, Houston TX, Shirley NY
Sponsor: Eli Lilly and Company
Sex: Female
Age: 18+
Code: NCT07287098
Phase2, Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Nashville TN, Peoria IL, Boston MA
Sponsor: Nerviano Medical Sciences
Sex: All
Age: 18+
Code: NCT06931626
Phase1, Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
for
Somatostatin Receptor Positive (SSTR+),
Location: Nashville TN, Atlanta GA, Edgewood KY, Wytheville VA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 12 - 70+
Code: NCT06784752
Phase3, Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
for
Non-Hodgkin Lymphoma Refractory/ Relapsed,
Location: Nashville TN, St Louis MO, Buffalo NY, New York NY,
Sponsor: LTZ Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07121946
Phase1, Recruiting
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
for
Ovarian Cancer
Location: Nashville TN, St Louis MO, Peoria IL, Houston TX,
Sponsor: Nerviano Medical Sciences
Sex: Female
Age: 18+
Code: NCT06930755
Phase1, Recruiting
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
for
Advanced Stage Solid Tumors
Location: Nashville TN, Fairfax VA, Sarasota FL, New York NY
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07107230
Phase1, Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
for
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic,
Location: Nashville TN, Smyrna TN, Mount Juliet TN, Lebanon TN,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07144280
Phase3, Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
for
Myelodysplastic Syndrome, Anemia
Location: Nashville TN, Atlanta GA, Skokie IL, Kansas City MO,
Sponsor: Takeda
Sex: All
Age: 18+
Code: NCT07422480
Phase3, Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Location: Nashville TN, Hendersonville TN, Franklin TN, Smyrna TN,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07227415
Phase1, Phase2, Recruiting
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
for
Relapsed and/or Refractory Multiple Myeloma
Location: Nashville TN, Birmingham AL, Tampa FL, New York NY,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06153251
Phase1, Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
for
Patients With Non-Small Cell Lung Cancer
Location: Nashville TN, Franklin TN, Smyrna TN, Shelbyville TN,
Sponsor: OSE Immunotherapeutics
Sex: All
Age: 18+
Code: NCT06472245
Phase3, Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer